Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis.
about
Characterization of the chloroquine-induced mouse model of pruritus using an automated behavioural system.Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.Psoriasis: A STAT3-Centric View.Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study.
P2860
Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Tofacitinib improves pruritus ...... te to severe plaque psoriasis.
@en
Tofacitinib improves pruritus ...... te to severe plaque psoriasis.
@nl
type
label
Tofacitinib improves pruritus ...... te to severe plaque psoriasis.
@en
Tofacitinib improves pruritus ...... te to severe plaque psoriasis.
@nl
prefLabel
Tofacitinib improves pruritus ...... te to severe plaque psoriasis.
@en
Tofacitinib improves pruritus ...... te to severe plaque psoriasis.
@nl
P2093
P1476
Tofacitinib improves pruritus ...... te to severe plaque psoriasis.
@en
P2093
Carla Mamolo
Claudia de la Cruz
Diamant Thaçi
Hernan Valdez
Lotus Mallbris
Mandeep Kaur
Marjorie Buonanno
Matthias Augustin
Shuping Lan
Steven R Feldman
P304
1162-1170.e3
P356
10.1016/J.JAAD.2016.07.040
P407
P50
P577
2016-09-28T00:00:00Z